GlassScriptPhysician profile
Autumn Davis
NPI 1942328984
$5,632.89
in general payments reported to CMS, 2019-2025
37 companies · $1,363 in 2025
The $1,363 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $841 · 2022: $815 · 2023: $1,106 · 2024: $1,508 · 2025: $1,363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,977.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,976.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $697.42 | 2023-2025 | |
| Abbott Laboratories | $598.12 | 2021-2025 | Freestyle Libre 3 |
| Abbvie INC. | $472.90 | 2021-2025 | |
| Radius Health, INC. | $447.41 | 2021-2025 | Tymlos |
| Medtronic, INC. | $318.63 | 2021-2025 | Minimed 780g |
| Xeris Pharmaceuticals, INC. | $317.07 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Dexcom, INC. | $258.88 | 2021-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $252.86 | 2021-2025 | Mounjaro, Zepbound, Baqsimi |
| Ascendis Pharma Endocrinology INC | $242.74 | 2022-2025 | Skytrofa |
| Tandem Diabetes Care, INC. | $222.41 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Rhythm Pharmaceuticals, INC. | $220.57 | 2022-2025 | Imcivree |
| Insulet Corporation | $215.64 | 2023-2024 | Omnipod |
| Azurity Pharmaceuticals, INC. | $196.68 | 2023-2025 | Triptodur, Triptodur |
| Novo Nordisk INC | $162.40 | 2021-2022 | |
| Corcept Therapeutics | $123.07 | 2021-2025 | Korlym |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $104.34 | 2022-2024 | |
| Beta Bionics, INC. | $96.93 | 2023-2024 | Ilet Bionic Pancreas |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.62 | 2021-2023 | Jardiance |
| Amgen INC. | $66.16 | 2021-2023 | Repatha |
| Tolmar, INC. | $46.21 | 2024-2025 | Fensolvi |
| Ultragenyx Pharmaceutical INC. | $45.16 | 2021 | |
| Biomarin Pharmaceutical INC. | $41.24 | 2024-2025 | Voxzogo 1.2mg |
| Arbor Pharmaceuticals, INC. | $39.23 | 2021-2022 | |
| Amarin Pharma, INC. | $39.20 | 2021 | |
| Sequel Med Tech, LLC | $37.65 | 2025 | Twiist |
| Boston Scientific Corporation | $37.51 | 2024-2025 | Watchman Flx |
| Amneal Pharmaceuticals LLC | $31.52 | 2021 | |
| Kyowa Kirin, INC. | $27.81 | 2023-2025 | Crysvita |
| Pfizer INC. | $27.68 | 2021-2024 | |
| Madrigal Pharmaceuticals | $26.59 | 2025 | Rezdiffra |
| Chiesi USA, INC. | $25.00 | 2025 | Mycapssa |
| Recordati_rare_diseases_inc. | $20.78 | 2023 | Isturisa, Signifor Lar |
| Alexion Pharmaceuticals, INC. | $20.20 | 2023 | Strensiq |
| Ibsa Pharma INC. | $19.03 | 2024 | Tirosint, Licart |
| Abiomed | $15.21 | 2024 | Impella |
| Cequr Corporation | $13.72 | 2024 | Cequr Simplicity |
| Amryt Pharma Holdings LTD | $11.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Autumn Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.